340B Pharmacy Safeguards Against Rx Diversion, Double Discounts Are Inconsistent – OIG
This article was originally published in The Pink Sheet Daily
The HHS Office of Inspector General documents discrepancies among 340B providers in how they ensure contract pharmacies comply with requirements about eligible patients and preventing Medicaid rebates on 340B-discounted drugs. The report will aid HRSA’s development of a comprehensive 340B rule that will address those issues.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.